Diagnosis of bacterial blood stream infections in coronavirus disease 2019 (COVID-19) using 16S rRNA sequencing method

Authors

  • Hassan Jabbar S.
  • Hassan Fuad Ghazi
  • Zaidan Ali

DOI:

https://doi.org/10.51248/.v41i2.802

Keywords:

COVID-19, bacterial blood stream infection, 16S rRNA sequencing, Serratia marcescens, Achromobacterxylosoxidans

Abstract

Introduction and Aim: Patients, who are positive for Coronavirus disease 2019 in association with bacterial co-infection may be more severe, the treatment is more problematic, and the treatment cycle is prolonged overall. This study aims to investigate bacterial blood stream infection in Coronavirus disease 2019 using 16S rRNA sequencing methods.

 

Materials and Methods: Two ml leftover blood samples from 50 patients with laboratory confirmed RT-PCR positive for Coronavirus disease 2019, who got admitted to the intensive care unit (ICU) in Quarantine Center in Baghdad, Iraqi were enrolled in this clinical case series study.

 

Results: The total of 13 positive sample PCR products were sequenced. The sequencing-based identification of these isolates included: Serratia marcescens,Achromobacterxylosoxidans, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus.

 

Conclusion:The significance of considering bacterial blood infection in Coronavirus disease 2019 patients even in the setting of a blood cultures are negative and clinicians ought to know about Serratia marcescens an A. xylosoxidans while treating Coronavirus disease 2019 patients due to resistant pattern to many antimicrobial agents.

Author Biographies

Hassan Jabbar S.

Department of Microbiology, College of Medicine, Al-Nahrain University, Iraq

Hassan Fuad Ghazi

Department of Medical Microbiology/Immunity/ Al-Mustaqbal University College, Iraq

Zaidan Ali

Al-Yarmouk Teaching Hospital, Ministry of Health, Iraq

References

World Health Organization. Laboratory biosafety guidance related to coronavirus disease (?COVID-19)?: interim guidance, 13 May 2020. World Health Organization; 2020.

Mullis, K., Erlich, H. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988;239(4839):487-491.

Quah, P., Li, A., Phua, J. Mortality rates of patients with COVID-19 in the intensive care unit: A systematic review of the emerging literature. Crit Care 2020; 24:285.

Singer, M., Deutschman, C., Seymour, C., Shankar, M., Annane, D., Bauer, M. et al., The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA2016; 315:801-810.

Shah, N., Greenberg, J., McNulty, M., Gregg, K., Riddell, J., Mangino, J., Bacterial and viral co-infections complicating severe influenza: incidence and impact among 507 US patients, 2013e14. J Clin Virol 2016; 80:12e9

Martín, I., Sanchez, A., Diaz, E., Granada, R., Zaragoza, R., Villavicencio, C. et al., Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest 2011; 139:555e62

Yang, X., Yu, Y., Xu, J., Shu, H., Liu, H., Wu, Y., et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centred, retrospective, observational study. The Lancet Respiratory Medicine. 2020 May 1;8(5):475-481.

Huttner, B., Catho, G., Pano-Pardo, J.R. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect 2020; 26:808e10.

Cates, J., Lucero, C., Dahl, R., Schirmer, P., Garg, S., Oda, G., et al., Risk for In-Hospital Complications Associated with COVID-19 and Influenza—Veterans Health Administration, United States, October 1, 2018–May 31, 2020. Morbidity and Mortality Weekly Report. 2020 Oct 23;69(42):1528.

Alhazzani, W., Møller, M., Arabi, Y., Loeb, M., Gong, M., Fan, E., et al., Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive care medicine. 2020 May;46(5):854-887.

Ruuskanen, O., Lahti, E., Jennings, L.C. Viral pneumonia. The Lancet. 2011 Apr 9;377(9773):1264-1275.

Sepulveda, J., Westblade, F., Whittier, S., Satlin, J., Greendyke, W., Aaron, J., et al., Bacteremia and blood culture utilization during COVID-19 surge in New York City. Journal of clinical microbiology. 2020 Jul 23;58(8).

Bizzarro, M.J., Dembry, L.M., Baltimore, R.S. Case-control analysis of endemic Serratia marcescens bacteremia in a neonatal intensive care unit Arch Dis Child Fetal Neonatal Ed. 2007;92: F120–F126. doi: 10.1136/adc.2006.102855

Lefort, A., Righi, S., Jauréguy, F., Bégué, T., Robineau, M., Bouchaud, O., Serratia marcescens prosthesis infection successfully treated with meropenem after imipenem failure. Journal of Infection. 2005 Aug 1;51(2): E45-E47.

Turgutalp, K., Kiykim, A., Ersoz, G. Fatal catheter-related bacteremia due to Alcaligenes (Achromobacter) xylosoxidans in a hemodialysis patient. International urology and nephrology. 2012 Aug 1;44(4):1281-1283.

Turel, O., Kavuncuoglu, S., Hosaf, E., Ozbek, S., Aldemir, E., Uygur, T. Bacteremia due to Achromobacterxylosoxidans in neonates: clinical features and outcome. Brazilian Journal of Infectious Diseases. 2013 Aug;17(4):450-454.

Aisenberg, G., Rolston, K.V., Safdar, A. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer. 2004; 101:2134-2140.

Gomez, J., Suárez, I., Ríos, J., Peña, P., Miguel, G., Jose, M., et al.,Achromobacterxylosoxidansbacteremia: a 10-year analysis of 54 cases. European Journal of Clinical Microbiology and Infectious Diseases. 2003 Jun;22(6):360-363.

Downloads

Published

2021-07-07

How to Cite

1.
Jabbar S. H, Fuad Ghazi H, Ali Z. Diagnosis of bacterial blood stream infections in coronavirus disease 2019 (COVID-19) using 16S rRNA sequencing method. Biomedicine [Internet]. 2021Jul.7 [cited 2021Jul.24];41(2):306-9. Available from: https://biomedicineonline.org/index.php/home/article/view/802

Issue

Section

Short Communications